PDCD1 and neoplasm: In various cancers, such as melanoma, PD-L1 can be expressed on the tumor cell surface and can bind to the T-cell receptor PD-1 to manipulate the immune checkpoint pathway, suppressing T-cell tumor attack and promoting tumor growth advantage (Grosso et al., 2013; Hamid et al., 2013).